Additional information
| Active substance | Pramiracetam |
|---|---|
| Chemical name | (S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine monohydrochloride |
| Side effects | Nausea, dizziness, hallucinations, insomnia, constipation, impulse control disorders |
| Effects | Improves motor control, reduces rigidity and tremors in Parkinson's patients |
| Dosage (sports) | Not applicable as it is not used for athletic enhancement |
| Dosage (medical) | Initial dose is typically 0.125 mg three times a day, may be increased gradually based on patient response and tolerability |
| Half-life | 8-12 hours |
| Main action | Mimics dopamine in the brain, used to treat symptoms of Parkinson’s disease |
| Substance class | Dopamine agonist |
| Formula | C10H17N3S В· HCl |
| Storage conditions | Store at room temperature away from moisture and heat |
| Trade name | Mirapex, Mirapex ER |
| Blood pressure | May cause orthostatic hypotension (drop in blood pressure when standing up) |
| WAREHOUSE | USA Warehouse 2 |
| Also known as | Pramipexole dihydrochloride |
| Lab Test | Not typically required for monitoring |
| Hepatotoxicity | Low risk |
| Water Retention | Minimal to none |
| Classification | Nootropic Stimulant of the Racetam Class |
| Active Half-Life | 4.5 to 6.5 hours |
| Use in sports | None, not recognized as a performance enhancing drug |
| Manufacturer | Spectre Labs |
Reviews
There are no reviews yet.